摘要
目的探讨帕金森病合并抑郁症采用丁苯酞治疗的临床效果及对脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)、5-羟色胺(5-hydroxytryptamine,5-HT)、血清神经营养因子-3(seRum nerve nutrition factor-3,NT-3)、C反应蛋白(C reactive protein,CRP)的影响。方法选取2013年9月—-2014年9月在我院接受治疗的80例帕金森病合并抑郁症患者,采用数字表法将患者分为对照组和观察组,每组40例。2组患者入院后均给予常规治疗,对照组患者给予美多芭和盐酸舍曲林片口服,观察组患者在对照组治疗的基础上给予丁苯酞软胶囊口服,疗程均为12周。对比2组临床治疗效果以及治疗前后汉密尔顿抑郁量表(HAMD)和帕金森统一分量表(UPDRS)评分、BDNF、5-HT、血清NT-3和DCRP水平。结果观察组临床总有效率与对照组相比明显较高,差异具有统计学意义(P<0.05)。观察组患者治疗后的HAMD评分和UPDRS评分与对照组相比明显较低,差异具有统计学意义(P<0.05)。2组患者治疗后的血清NT-3、BDNF、5-HT水平明显高于治疗前(P<0.05),2组患者治疗后的CRP水平明显低于治疗前(P<0.05);观察组患者治疗后的血清NT-3、BDNF、5-HT水平明显高于对照组,CRP水平明显低于对照组,差异具有统计学意义(P<0.05)。结论丁苯酞可以明显改善帕金森病合并抑郁症患者的抑郁症状,明显降低血清CRP水平,明显提高BDNF、5-HT、血清NT-3水平,效果显著,建议推广。
Objective To investigate the clinical effect of butylphthalide in the treatment of depression in Parkinson＇s disease and the influence on the brain-derivedneurotrophic factor （BDNF）, 5-hydroxytryptamine （5-HT）, serum neurotrophic factor3 （NT-3）, and C reactive protein （CRP）. Methods Eighty patients of Parkinson＇s disease with depression who had received treatment in our hospital from September 2013 to September 2016 were evenly divided into the control group and the observation group. Both groups were given conventional treatment after admission. The control group was treated with madopar and sertraline hydrochloride, while the observation group was given butylphthalide soft capsules in addition to madopar and sertraline hydrochloride. The course of treatment was 12 weeks. The therapeutic effect, changes of HAMD and UPDRS scores, and levels of BDNF, 5-HT serum NT-3 and CRP were compared between the two groups. Results The clinical efficacy in the observation group was higher than that in the control group, and the difference was statistically significant （P〈0.05）. The scores of HAMD and UPDRS in the observation group were lower than those in the control group, and the difference was statistically significant （P〈0.05）, The serum level of NT-3, BDNF, level of 5-HT in the two groups was significantly increased after treatment, so was the level of CRP in the two groups. The level of serum NT-3, BDNF, and level of 5-HT in the observation group was higher than that in the control group, and the difference was statistically significant （P〈0.05）. Conclusion Butylphthalide can significantly improve symptoms of depression among patients of Parkinson＇s disease, decrease the serum level of CRP, and increase the serum level of NT-3. This therapy is effective and worthy of recommendation.
出处
《空军医学杂志》
2016年第5期330-333,共4页
Medical Journal of Air Force
关键词
帕金森病
抑郁
丁苯酞
脑源性神经营养因子
5-羟色胺
Parkinson＇s disease
Depression
Butylphthalide
Drain-derived neurotrophic factor
5-hydroxytryptamine
